A NEW ERA OF IMMUNE BIOMARKERS

Compelling insights powered by our analytical engine ImmunoINSIGHTS™
The leading antibody biomarker discovery platform to advance precision medicine

Our Technology & Science

ImmunoINSIGHTS™ the analytical engine adding insights to your clinical data

Oncimmune has developed the most advanced and comprehensive analytical platform for the discovery of Antibody / Autoantibody Biomarker Signatures. ImmunoINSIGHTS™, the best-in-class biomarker discovery engine, provides access to the B cell repertoire and a pivotal class of biomarkers.

With one of the world’s largest antigen libraries covering 9000+ human antigens and multi-species variants, we profile antibodies from various biologic samples in very low volume (50 µl). Developed and curated by immunologists and a team of bioinformaticians, we offer high content biological insights and analytics powered by proprietary machine learning algorithms, models and deep knowledge mining solutions.  Our platform uses Luminex xMAP® – the world’s most used multiplexing technology.

At Oncimmune, our mission is to develop innovative technologies and solutions to improve the understanding of the immune system leading to more effective, targeted and safer treatments and better diagnosis. Our scientists work hand-in-hand with our clients to discover relevant and insightful biomarkers.

Learn more

Robust & Reproducible

Bead-based multiplexed immunoassay Luminex xMAP® Technology

Largest Antigen Library

9000+  human antigens  & multi-species variants available for interrogation

Minimal Sample Volume

<50 µl per sample
(serum, plasma and others)

High-Throughput

Large numbers of samples through automated robotic workflows

Rapid & Reliable

Tailored to your projects

Panel Customization

Tailored to specific studies

Collaborative

Ongoing partnering and communications

Advanced Bioinformatics & Data Science

Advanced data insights, analytics and the flexibility of multiomics data integration

Broad Expertise in Immunology

Our proprietary platform, ImmunoINSIGHTS™ can be applied across different therapeutic and disease areas for a wide range of biomarker applications

Our Services

Explore our services and learn how we can provide biomarker insights to advance your next generation therapies.

ImmunoINSIGHTS
Biomarker Discovery

More

ImmunoINSIGHTS
Targeted Panels & Arrays

More

Bioinformatics & Data Science

More

Resources

Oncimmune’s CEO, Martin Gouldstone speaks to Vox Market about the company’s new strategy progress.

Read Article

Martine Gouldstone, CEO updates investors on Oncimmune’s new strategy

Read Article
View more

News

Oncimmune announces strategy updates and changes to the board of directors.

Read Article

Oncimmune receives Queen’s Award for Enterprise in Innovation 2022

Read Article

Oncimmune signs contracts with US-based clinical-stage biopharmaceutical companies developing immunotherapies one of which is focused on CAR NK cell therapies.

Read Article

Begin your project today!

Contact us